Overactive Bladder Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

Las Vega (Nevada), United States //— As per DelveInsight’s assessment, globally, Overactive Bladder pipeline constitutes 15+ key companies continuously working towards developing 15+ Overactive Bladder treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

Overactive Bladder Overview
Overactive bladder (OAB) is the name for a group of urinary symptoms. It is not a disease. The most common symptom is sudden, uncontrolled need or urge to urinate. The definition of OAB updated in 2010 by the International Continence Society is:A condition with characteristic symptoms of “urinary urgency, usually accompanied by frequency and nocturia, with or without urgency incontinence, in the absence of urinary tract infection or other obvious pathology

“Overactive Bladder Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Overactive Bladder Market.

The Overactive Bladder Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Overactive Bladder Pipeline Report:
• Companies across the globe are diligently working toward developing novel Overactive Bladder treatment therapies with a considerable amount of success over the years. Overactive Bladder Key players such as – Aardvark Therapeutics, Exxel Pharma, Hugel, Imbrium Therapeutics, Taiho Pharmaceutical, Sumitovant Biopharma, Dong-A ST, and others, are developing therapies for the Overactive Bladder treatment
• Overactive Bladder Emerging therapies such as – ARD-380, URB937, Botulax, IMB-115, TAC-302, URO-902, DA-8010, and others are expected to have a significant impact on the Overactive Bladder market in the coming years.
• In May 2022, Dong-A ST initiated a multicenter, double-blind, placebo-controlled and active-reference, randomized, parallel, therapeutic confirmatory clinical study to evaluate the efficacy and safety of da-8010 in patients with overactive bladder
• In September 2022, Urovant Sciences, a wholly owned subsidiary of Sumitovant Biopharma Ltd., receives coveted Best in Category award for an interim 12-week analysis from the ongoing Phase II a trial of an investigational novel gene therapy product, URO-902 (plasmid human cDNA encoding maxi-K channel).
• In March 2021, Sumitovant Biopharma acquired all the outstanding shares of Urovant Sciences and after acquisition Urovant Sciences become the subsidiary of Sumitovant Biopharma. Through this acquisition, Sumitovant Biopharma acquired all products of Urovant Sciences

Route of Administration
Overactive Bladder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Molecule Type
Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Overactive Bladder Pipeline Therapeutics Assessment
• Overactive Bladder Assessment by Product Type
• Overactive Bladder By Stage and Product Type
• Overactive Bladder Assessment by Route of Administration
• Overactive Bladder By Stage and Route of Administration
• Overactive Bladder Assessment by Molecule Type
• Overactive Bladder by Stage and Molecule Type

DelveInsight’s Overactive Bladder Report covers around 15+ products under different phases of clinical development like-
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Some of the key companies in the Overactive Bladder Therapeutics Market include:
Key companies developing therapies for Overactive Bladder are – AbbVie, Medytox, Velicept Therapeutics, Sumitovant Biopharma, Hugel, Imbrium Therapeutics, Lipella Pharmaceuticals, Bayer, Sumitovant Biopharma, Aetas Pharma, and others.

Emerging Overactive Bladder Drugs Under Different Phases of Clinical Development Include:
• ARD-380: Aardvark Therapeutics
• URB937: Exxel Pharma
• Botulax: Hugel
• IMB-115: Imbrium Therapeutics
• TAC-302: Taiho Pharmaceutical
• URO-902: Sumitovant Biopharma
• DA-8010: Dong-A ST

Get a Free Sample PDF Report to know more about Overactive Bladder Pipeline Therapeutic Assessment

Overactive Bladder Pipeline Analysis:
The Overactive Bladder pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Overactive Bladder with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Overactive Bladder Treatment.
• Overactive Bladder key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Overactive Bladder Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Overactive Bladder market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Overactive Bladder product details are provided in the report. Download the Overactive Bladder pipeline report to learn more about the emerging Overactive Bladder therapies

Overactive Bladder Pipeline Market Drivers
• Prevalence of urinary incontinence
• Approval of generics
• Growth in the number of product launches

Overactive Bladder Pipeline Market Barriers
• Lack of diagnosis and information about Overactive Bladder
• Side effects associated with the current treatment options

Scope of Overactive Bladder Pipeline Drug Insight
• Coverage: Global
• Key Overactive Bladder Companies: Aardvark Therapeutics, Exxel Pharma, Hugel, Imbrium Therapeutics, Taiho Pharmaceutical, Sumitovant Biopharma, Dong-A ST, and others
• Key Overactive Bladder Therapies: ARD-380, URB937, Botulax, IMB-115, TAC-302, URO-902, DA-8010, and others
• Overactive Bladder Therapeutic Assessment: Overactive Bladder current marketed and Overactive Bladder emerging therapies
• Overactive Bladder Market Dynamics: Overactive Bladder market drivers and Overactive Bladder market barriers

Request for Sample PDF Report for Overactive Bladder Pipeline Assessment and clinical trials

Table of Contents
1 Overactive Bladder Report Introduction
2 Overactive Bladder Executive Summary
3 Overactive Bladder Overview
4 Overactive Bladder- Analytical Perspective In-depth Commercial Assessment
5 Overactive Bladder Pipeline Therapeutics
6 Overactive Bladder Late Stage Products (Phase II/III)
7 Overactive Bladder Mid Stage Products (Phase II)
8 Overactive Bladder Early Stage Products (Phase I)
9 Overactive Bladder Preclinical Stage Products
10 Overactive Bladder Therapeutics Assessment
11 Overactive Bladder Inactive Products
12 Company-University Collaborations (Licensing/Partnering) Analysis
13 Overactive Bladder Key Companies
14 Overactive Bladder Key Products
15 Overactive Bladder Unmet Needs
16 Overactive Bladder Market Drivers and Barriers
17 Overactive Bladder Future Perspectives and Conclusion
18 Overactive Bladder Analyst Views
19 Appendix
20 About DelveInsight
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report to know more about Overactive Bladder drugs and therapies

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
www.delveinsight.com/consulting